A carregar...

Feasibility and Safety of Systemic rAAV9-hNAGLU Delivery for Treating Mucopolysaccharidosis IIIB: Toxicology, Biodistribution, and Immunological Assessments in Primates

No treatment is currently available for mucopolysaccharidosis (MPS) IIIB, a neuropathic lysosomal storage disease caused by autosomal recessive defect in α-N-acetylglucosaminidase (NAGLU). In anticipation of a clinical gene therapy treatment for MPS IIIB in humans, we tested the rAAV9-CMV-hNAGLU vec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Murrey, Darren A., Naughton, Bartholomew J., Duncan, F. Jason, Meadows, Aaron S., Ware, Tierra A., Campbell, Katie J., Bremer, William G., Walker, Christopher M., Goodchild, Laurie, Bolon, Brad, La Perle, Krista, Flanigan, Kevin M., McBride, Kim L., McCarty, Douglas M., Fu, Haiyan
Formato: Artigo
Idioma:Inglês
Publicado em: Mary Ann Liebert, Inc. 2014
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4124586/
https://ncbi.nlm.nih.gov/pubmed/24720466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/humc.2013.208
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!